Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact sciences

ISIN: US30063P1057 , WKN: 590273

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

2024-11-13
MADISON, Wis., November 13, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening

Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter

2024-11-11
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund returned 9.15% while the benchmark, the Russell 2500 Growth Index, returned 6.99%. A strong market rally occurred throughout the quarter, and the Columbia Acorn Fund beat its benchmark […]

Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.

2024-11-10
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong investment potential.

Exact Sciences’ forecast cut shocks analysts

2024-11-08
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock.

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

2024-11-07
Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Guardant Health Rockets 25% On An 'Impressive' Beat Following Exact Sciences' Flop

2024-11-07
Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Exact Sciences Third Quarter 2024 Earnings: Misses Expectations

2024-11-07
Exact Sciences ( NASDAQ:EXAS ) Third Quarter 2024 Results Key Financial Results Revenue: US$708.7m (up 13% from 3Q...

Columbia Acorn Fund Q3 2024 Investment Commentary

2024-11-07
Institutional Class shares of Columbia Acorn Fund returned 9.15% in the third quarter. Read more here.

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

2024-11-06
Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook.

Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount

2024-11-06
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.